<div id="readability-page-1"><div><ul> <li>In recent days, Procter &amp; Gamble’s Pantene brand expanded its influencer push by launching a limited‑edition “As seen in Alix’s Shower” Abundant &amp; Strong kit with creator Alix Earle, while the company also confirmed the planned 2026 retirement of long‑time Health Care CEO Jennifer Davis.</li> <li>Together with prior announcements on European logistics expansion and portfolio pruning, these moves highlight how P&amp;G is refining its brand reach while tightening its operational footprint.</li> <li>We’ll now examine how Pantene’s Alix Earle collaboration and P&amp;G’s broader expansion efforts may influence the company’s existing investment narrative.</li> </ul><p>The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</p><h2>Procter &amp; Gamble Investment Narrative Recap</h2><p>To own Procter &amp; Gamble, you need to believe its global brands and steady cash flows can offset slower category growth and consumer volatility, particularly in the U.S. and Europe. The Pantene Alix Earle collaboration and Jennifer Davis’s planned retirement do not materially change the near term focus on the January 22 earnings webcast and on volume trends vs pricing, nor do they reduce key risks from softer demand and cost inflation.</p> <p>The most relevant recent announcement here is P&amp;G’s expansion of its European logistics network with a 37,000 square meter Prague facility, expected to support operations from 2027. While separate from Pantene’s influencer push, it sits on the same continuum of P&amp;G refining reach and efficiency as it tackles near term risks around consumer and retailer volatility and external cost pressures.</p> <p>Yet investors should be aware that softer consumer demand in key markets could...</p> <p>Read the full narrative on Procter &amp; Gamble (it's free!)</p><p>Procter &amp; Gamble's narrative projects $92.8 billion revenue and $17.8 billion earnings by 2028. This requires 3.3% yearly revenue growth and an earnings increase of about $2.1 billion from $15.7 billion today.</p><p>Uncover how Procter &amp; Gamble's forecasts yield a $168.50 fair value, a 17% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ec4c27dd-9326-4d1d-abbf-e6e7b1f4fc61/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ec4c27dd-9326-4d1d-abbf-e6e7b1f4fc61/chart/quote-price"/><figcaption>PG 1-Year Stock Price Chart</figcaption></figure> <p>Nineteen members of the Simply Wall St Community value P&amp;G between US$119.81 and US$194.19, underscoring how differently its prospects are viewed. Set these views against ongoing concerns about consumer and retailer volatility and you can see why it pays to compare several perspectives before deciding how P&amp;G might fit in your portfolio.</p><p>Explore 19 other fair value estimates on Procter &amp; Gamble - why the stock might be worth as much as 34% more than the current price!</p><h2>Build Your Own Procter &amp; Gamble Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Procter &amp; Gamble research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.</li><li>Our free Procter &amp; Gamble research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Procter &amp; Gamble's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:</p><ul><li>We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</li><li>Find companies with promising cash flow potential yet trading below their fair value.</li><li>These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

<p>Procter & Gamble is refining its brand reach and operational footprint with Pantene's influencer collaboration and European logistics expansion. Investors are evaluating these moves alongside the planned retirement of Health Care CEO Jennifer Davis. P&G's narrative projects $92.8 billion revenue and $17.8 billion earnings by 2028, with a fair value of $168.50, offering a 17% upside. Analysts have varied valuations, highlighting the importance of diverse perspectives in investment decisions.</p>

How Investors Are Reacting To Procter & Gamble (PG) Influencer Push And Leadership Transition